HPRTKMAG-01K

MILLIPLEX ^®RTK磷蛋白磁珠板-细胞信号转导多重检测试剂盒

Name: MILLIPLEX <SUP>®</SUP>RTK磷蛋白磁珠板-细胞信号转导多重检测试剂盒
Brand: MM

Configurable RTK Phosphoprotein 16-Plex Cell Signaling Panel

登录查看组织和合同定价。

关于此项目

UNSPSC Code:

12161503

NACRES:

NA.47

eCl@ss:

32161000

主要文件

查看所有文档

技术服务

需要帮助？我们经验丰富的科学家团队随时乐意为您服务。

让我们为您提供帮助

产品名称

MILLIPLEX ^®RTK磷蛋白磁珠板-细胞信号转导多重检测试剂盒, Configurable RTK Phosphoprotein 16-Plex Cell Signaling Panel

species reactivity

human

Quality Level

200

packaging

pkg of 1 ea

manufacturer/tradename

Milliplex^®

technique(s)

multiplexing: suitable

detection method

fluorometric (Luminex^® xMAP^® technology)

shipped in

wet ice

storage temp.

2-8°C

Legal Information

Luminex is a registered trademark of Luminex Corp

MILLIPLEX is a registered trademark of Merck KGaA, Darmstadt, Germany

xMAP is a registered trademark of Luminex Corp

Application

MILLIPLEX^® Qualified assays undergo rigorous assay development, verification, and Quality Control testing to achieve optimal performance. Simultaneously analyze up to 16 analytes in cell lysate samples.Analytes Included: phosphorylated (panTyr) c-Kit, c-Met/HGFR, EGFR, ErbB2/HER2, ErbB3/HER3 , ErbB4/HER4 , FGFR1 , FLT3 , IGF-1R, M-CSFR, PDGFRβ, TIE1, TIE2, VEGFR1, VEGFR2, and VEGFR3Assay Characteristics: Refer to the assay protocol for details on cross-reactivity, buffer compatibility, lysate control, and recommended loading control (MAPmate™ Control Assays).

Disclaimer

For research use only. Not for use in diagnostic procedures.Label License/Sticker for Assay Product:By opening the packaging containing this Assay Product (which contains fluorescently labeled microsphere beads authorized by Luminex Corporation) or using this Assay Product in any manner, you are consenting and agreeing to be bound by the End User Terms and Conditions and the End User License Agreement available at http://support.diasorin.com/end-user-terms-and-conditions/. If you do not agree to all of the terms and conditions, you must promptly return this Assay Product for a full refund prior to using it in any manner.

Features and Benefits

• Simultaneously detect multiple phosphorylated receptor tyrosine kinases (RTKs) involved in cell growth, survival, and differentiation• Includes key RTKs such as EGFR, HER2, VEGFR, PDGFR, and others• Magnetic bead-based format ensures reproducibility and efficient processing• Compatible with cell lysates from cancer, immunology, and signal transduction studies• Ideal for oncology, drug discovery, and receptor signaling research• Fast, convenient alternative to Western Blotting and immunoprecipitation procedures

General description

This panel targets phosphorylated receptor tyrosine kinases (RTKs), which are essential mediators of cell signaling in response to growth factors and cytokines. RTKs such as EGFR, HER2, VEGFR, and PDGFR regulate pathways involved in cell proliferation, survival, and differentiation. Aberrant RTK activation is associated with cancer, making this panel valuable for oncology and signal transduction research.

pictograms

GHS05,GHS07,GHS09

signalword

Danger

hcodes

H302,H315,H318,H410

pcodes

P264 - P273 - P280 - P301 + P312 - P302 + P352 - P305 + P351 + P338

Hazard Classifications

Acute Tox. 4 Oral - Aquatic Acute 1 - Aquatic Chronic 2 - Eye Dam. 1 - Skin Irrit. 2

存储类别

10 - Combustible liquids

法规信息

新产品

此项目有

分析证书(COA)

输入产品批号来搜索分析证书(COA) 。批号可以在产品标签上"批“ （Lot或Batch）字后找到。

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

Differences in Signaling Patterns on PI3K Inhibition Reveal Context Specificity in KRAS-Mutant Cancers.

Adam Stewart et al.

Molecular cancer therapeutics, 18(8), 1396-1404 (2019-07-03)

It is increasingly appreciated that drug response to different cancers driven by the same oncogene is different and may relate to differences in rewiring of signal transduction. We aimed to study differences in dynamic signaling changes within mutant KRAS (KRAS

Individualized Prediction of Drug Response and Rational Combination Therapy in NSCLC Using Artificial Intelligence-Enabled Studies of Acute Phosphoproteomic Changes.

Elizabeth A Coker et al.

Molecular cancer therapeutics, 21(6), 1020-1029 (2022-04-04)

We hypothesize that the study of acute protein perturbation in signal transduction by targeted anticancer drugs can predict drug sensitivity of these agents used as single agents and rational combination therapy. We assayed dynamic changes in 52 phosphoproteins caused by

Exploiting evolutionary steering to induce collateral drug sensitivity in cancer.

Ahmet Acar et al.

Nature communications, 11(1), 1923-1923 (2020-04-23)

Drug resistance mediated by clonal evolution is arguably the biggest problem in cancer therapy today. However, evolving resistance to one drug may come at a cost of decreased fecundity or increased sensitivity to another drug. These evolutionary trade-offs can be

MILLIPLEX ^®RTK磷蛋白磁珠板-细胞信号转导多重检测试剂盒